SCHEMBL8861950

SCHEMBL8861950

COC(=O)CC[C@@H](C(=O)O)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 1/20 0.42
CA12 O43570 2/20 0.41
CA2 P00918 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA1 P00915 1/20 0.41
MMP13 P45452 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 1/20 0.36
AAK1 Q2M2I8 2/20 0.35
TSHR P16473 3/20 0.35
REN P00797 1/20 0.35
SELP P16109 3/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HPGD P15428 1/20 0.31
RECQL P46063 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31407405 1.00 SLC1A1 (0.42) SLC1A1CA12CA2CA14CA1
SCHEMBL31556032 0.88 CA12 (0.41) SLC1A1CA12CA2CA14CA1
SCHEMBL20089217 0.88 CA12 (0.41) SLC1A1CA12CA2CA14CA1
SCHEMBL1197166 0.86 SLC1A1 (0.43) SLC1A1CA12CA2CA14CA1
SCHEMBL28457371 0.86 FOLH1 (0.38) SLC1A1MMP13MEN1KMT2AGAA
SCHEMBL13598307 0.86 REN (0.40) SLC1A1CA12CA2CA14CA1
SCHEMBL3899118 0.86 REN (0.40) SLC1A1CA12CA2CA14CA1
SCHEMBL18248185 0.86 REN (0.40) SLC1A1CA12CA2CA14CA1
SCHEMBL8906653 0.86 FOLH1 (0.38) SLC1A1MMP13MEN1KMT2AGAA
SCHEMBL21510658 0.85 CA12 (0.40) SLC1A1CA12CA2CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 EP disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 US disclosed
US-5606028-A Anchimeric radiometal chelating compounds NEORX CORPORATION (US) 1997-02-25 US disclosed
US-5202451-A ANCHIMERIC RADIOMETAL CHELATING COMPOUNDS NEORX CORPORATION (US) 1993-04-13 US disclosed
EP-0329481-A2 Anchimeric radiometal chelating compounds NEORX CORPORATION (US) 1989-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 SLC1A1 3262/4885CA12 2253/4885CA2 2993/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP SLC1A1 3143/4885CA12 1749/4885CA2 2379/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP SLC1A1 2940/4885CA12 1975/4885CA2 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.